Zevra Therapeutics, Inc. (ZVRA)
| Market Cap | 689.45M +67.5% |
| Revenue (ttm) | 136.07M +119.4% |
| Net Income | 57.25M +2,103.6% |
| EPS | 0.96 |
| Shares Out | 59.38M |
| PE Ratio | 12.09 |
| Forward PE | 13.61 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,481,693 |
| Open | 11.76 |
| Previous Close | 11.84 |
| Day's Range | 11.52 - 11.93 |
| 52-Week Range | 7.36 - 15.04 |
| Beta | 0.95 |
| Analysts | Strong Buy |
| Price Target | 25.00 (+115.33%) |
| Earnings Date | Nov 4, 2026 |
About ZVRA
Zevra Therapeutics, Inc., a commercial-stage company, focuses on addressing unmet needs for the treatment of rare diseases in the United States. The company develops its products through Ligand Activated Technology platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 3 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase 3 clinical trial to treat narcolepsy. The company is developing Celiprolol, an investigational product candidate that is under Phase 3 clinical tr... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 9 analysts, the average rating for ZVRA stock is "Strong Buy." The 12-month stock price target is $25.0, which is an increase of 115.33% from the latest price.
News
Zevra Therapeutics Transcript: H.C. Wainwright 28th Annual Global Investment Conference
Significant progress includes expanding the diagnosed population for MIPLYFFA, leveraging updated clinical guidelines, and investing in data-driven patient identification. Global expansion and a strong balance sheet support ongoing pipeline development and strategic flexibility.
Zevra Therapeutics Transcript: Morgan Stanley 24th Annual Global Healthcare Conference
Focused on redefining rare disease care, the company has rapidly grown its U.S. market for Niemann-Pick type C, expanded globally, and advanced a promising pipeline. Strong financials and robust patient support underpin its strategy, with key regulatory and clinical milestones ahead.
Zevra Therapeutics Slides: Corporate presentation
Zevra Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on September 14, 2026.
Zevra Therapeutics Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference
The conference highlighted robust commercial progress in rare diseases, with strong U.S. and global expansion for NPC, a growing adult patient base, and a well-capitalized position. Ongoing regulatory efforts and a solid pipeline, including VEDS, support long-term growth.
Zevra Therapeutics to Present at Upcoming Investor Conferences
BOSTON, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on bringing life-changing therapeutics to people living...
Zevra Therapeutics to Present New Long-Term Real-World Data on MIPLYFFA® in Niemann-Pick Disease Type C (NPC) at the 2026 SSIEM Annual Symposium
BOSTON, Aug. 25, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on bringing life-changing therapeutics to people living ...
Zevra Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
BOSTON, Mass., Aug. 21, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on bringing life-changing therapeutics to people ...
Zevra Therapeutics Transcript: Canaccord Genuity's 46th Annual Growth Conference
MIPLYFFA's U.S. launch is driving growth in both adult and pediatric Niemann-Pick type C patients, with integrated strategies expanding the addressable market. European expansion is ongoing, and the pipeline includes a late-stage program for Vascular Ehlers-Danlos Syndrome. Strong financials support disciplined investment and targeted business development.
Zevra Therapeutics price target lowered to $23 from $24 at Guggenheim
Guggenheim analyst Eddie Hickman lowered the firm’s price target on Zevra Therapeutics (ZVRA) to $23 from $24 and keeps a Buy rating on the shares.
Zevra Therapeutics price target raised to $28 from $25 at Citizens
Citizens raised the firm’s price target on Zevra Therapeutics (ZVRA) to $28 from $25 and keeps an Outperform rating on the shares. Zevra reported strong Q2 results driven by MIPLYFFA…
Zevra Therapeutics Earnings Call Transcript: Q2 2026
Q2 2026 net revenue rose 53% year-over-year to $39.7 million, led by strong MIPLYFFA sales and expanding adoption in both pediatric and adult NPC patients. Cash reserves reached $260.2 million, supporting ongoing pipeline and global expansion, while regulatory re-examination for arimoclomol in Europe continues.
Zevra Therapeutics Earnings release: Q2 2026
Zevra Therapeutics released its Q2 2026 earnings on August 5, 2026, summarizing the period's financial results.
Zevra Therapeutics Quarterly report: Q2 2026
Zevra Therapeutics has published its Q2 2026 quarterly earnings report on August 5, 2026.
Zevra Reports Second Quarter 2026 Financial Results and Corporate Update
$39.7 million net revenue for Q2 2026, driven by $30.2 million in revenue from MIPLYFFA 53% increase in total net revenue over Q2 2025 Operational execution fueled strong cash position of $260.2 milli...
Zevra Therapeutics Slides: Corporate presentation
Zevra Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on August 5, 2026.
Zevra Therapeutics to Present at the Canaccord Genuity Annual Growth Conference
BOSTON, Aug. 04, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on bringing life-changing therapeutics to people living ...
Zevra Therapeutics Announces Publication of Four-Year Real-World Data from U.S. Early Access Program Evaluating MIPLYFFA® (arimoclomol) in Niemann-Pick Disease Type C (NPC)
Longitudinal study includes first published real-world data on arimoclomol in adults with NPC and provides insights across a broad patient population Longitudinal study includes first published real-w...
ZVRA Investors Have Opportunity to Join Zevra Therapeutics, Inc. Fraud Investigation with SBS Law
LOS ANGELES--(BUSINESS WIRE)--Schall, Brown & Schwartz LLP (“SBS”), a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Zevra Therapeutic...
Spruce Biosciences appoints Quartel as Chief Medical Officer
Spruce Biosciences (SPRB) announced the appointment of Adrian Quartel, M.D., FFPM, as Chief Medical Officer, effective today. Quartel joins Spruce from Zevra Therapeutics (ZVRA), where he served as Ch...
Zevra Therapeutics price target lowered to $24 from $29 at Guggenheim
Guggenheim lowered the firm’s price target on Zevra Therapeutics (ZVRA) to $24 from $29 and keeps a Buy rating on the shares after having caught up with management following the…
Zevra Therapeutics price target lowered to $24 from $27 at BTIG
BTIG analyst Kambiz Yazdi lowered the firm’s price target on Zevra Therapeutics (ZVRA) to $24 from $27 and keeps a Buy rating on the shares. The firm is citing the…
Zevra Therapeutics price target lowered to $20 from $29 at Canaccord
Canaccord lowered the firm’s price target on Zevra Therapeutics (ZVRA) to $20 from $29 and keeps a Buy rating on the shares. The firm updated its model following the European…
EU opinion ‘headwind, but not insurmountable’ for Zevra, says H.C. Wainwright
After Zevra Therapeutics (ZVRA) announced that the EMA’s Committee for Medicinal Products for Human Use adopted a negative opinion on the marketing authorization application, or MAA, for arimoclomol f...
Zevra Therapeutics down 30% at $8.78 after negative CHMP opinion on arimoclomol
08:22 EDT Zevra Therapeutics (ZVRA) down 30% at $8.78 after negative CHMP opinion on arimoclomol
Zevra Therapeutics announces negative CHMP opinion on arimoclomol MAA
Zevra Therapeutics (ZVRA) announced that the Committee for Medicinal Products for Human Use, or CHMP, of the European Medicines Agency, or EMA, has adopted a negative opinion regarding the marketing…